Company Description
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States.
The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other.
It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services.
The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies.
It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
| Country | United States |
| Founded | 2007 |
| Industry | Medical Care Facilities |
| Sector | Healthcare |
| Employees | 825 |
| CEO | Daniel Virnich |
Contact Details
Address: 18000 Studebaker Road, Suite 800 Cerritos, California 90703 United States | |
| Phone | 562 735 3226 |
| Website | theoncologyinstitute.com |
Stock Details
| Ticker Symbol | TOI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001799191 |
| CUSIP Number | 68236X100 |
| ISIN Number | US68236X1000 |
| Employer ID | 84-3562323 |
| SIC Code | 8011 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel Virnich FACHE, M.B.A., M.D. | Chief Executive Officer and Executive Director |
| Richard Alan Barasch | Chairman of the Board |
| Jeremy N. Castle M.B.A. | Chief Operations Officer |
| Dr. Yale D. Podnos F.A.C.S., M.D., M.P.H. | Chief Medical Officer |
| Robert Carter | Chief Financial Officer |
| Austin Lee | Vice President of Accounting and Controller |
| Mark Hueppelsheuser Esq. | General Counsel |
| Jordan McInerney | Chief Development Officer |
| Stephen Cella | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 8, 2025 | 8-K | Current Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 23, 2025 | SCHEDULE 13D/A | Filing |
| Apr 11, 2025 | 8-K | Current Report |
| Apr 8, 2025 | D | Notice of Exempt Offering of Securities |
| Mar 28, 2025 | SCHEDULE 13D/A | Filing |
| Mar 27, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 27, 2025 | DEF 14A | Other definitive proxy statements |